GlaxoSmithKline plc (LON:GSK) has been given a GBX 1,600 ($20.77) price target by analysts at UBS AG in a note issued to investors on Tuesday, August 1st, www.boersen-zeitung.de reports. The brokerage currently has a “neutral” rating on the stock. UBS AG’s price objective would indicate a potential upside of 7.38% from the stock’s current price.
A number of other equities analysts also recently issued reports on the stock. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a report on Friday, July 28th. Morgan Stanley set a GBX 1,700 ($22.07) target price on shares of GlaxoSmithKline plc and gave the company a “neutral” rating in a report on Thursday, July 27th. Credit Suisse Group restated a “neutral” rating and set a GBX 1,775 ($23.04) target price on shares of GlaxoSmithKline plc in a report on Thursday, July 27th. Kepler Capital Markets restated a “reduce” rating and set a GBX 1,520 ($19.73) target price on shares of GlaxoSmithKline plc in a report on Thursday, July 27th. Finally, Barclays PLC restated an “equal weight” rating and set a GBX 1,550 ($20.12) target price on shares of GlaxoSmithKline plc in a report on Thursday, July 27th. Four analysts have rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of GBX 1,724 ($22.38).
GlaxoSmithKline plc (LON:GSK) opened at 1490.00 on Tuesday. The stock’s market cap is GBX 72.83 billion. The firm has a 50-day moving average of GBX 1,564.93 and a 200-day moving average of GBX 1,621.93. GlaxoSmithKline plc has a 12-month low of GBX 1,446.50 and a 12-month high of GBX 1,745.56.
TRADEMARK VIOLATION WARNING: This report was first published by BNB Daily and is owned by of BNB Daily. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.baseball-news-blog.com/2017/08/19/glaxosmithkline-plc-gsk-given-a-gbx-1600-price-target-by-ubs-ag-analysts-updated-updated.html.
In other news, insider Patrick Vallance purchased 861 shares of GlaxoSmithKline plc stock in a transaction dated Friday, July 14th. The stock was bought at an average price of GBX 1,618 ($21.00) per share, with a total value of £13,930.98 ($18,085.14). Also, insider Manvinder Singh Banga purchased 2,267 shares of GlaxoSmithKline plc stock in a transaction dated Wednesday, July 26th. The shares were purchased at an average cost of GBX 1,599 ($20.76) per share, with a total value of £36,249.33 ($47,058.72). In the last quarter, insiders have acquired 3,151 shares of company stock valued at $5,054,922.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.